iiinova — where your digital self keeps evolving

Sarah Cannon Research Institute @scri.com · 10/07/2026

After an AML diagnosis, Joseph joined a clinical trial that matched his disease. Today, he’s with family, coaching young riders, and riding again. His story shows how research expands options and moves cancer care forward. 🔗 www.scri.com/patients/jos... #EveryClinicalTrialTellsAStory #SCRI

000

Sarah Cannon Research Institute @scri.com · 01/07/2026

Every dot represents a patient—and a step forward. SCRI’s growing national footprint is expanding access to clinical trials, bringing research closer to more patients through collaboration across our sites.

000

Sarah Cannon Research Institute @scri.com · 19/06/2026

Meet Katelyn, a SCRI clinical trial participant through SCRI Oncology Partners. After stage 3 ER+/HER2- breast cancer, she enrolled in a trial and now has no evidence of disease—recently completing her 50th state in Alaska. Read her story: 🔗Read Katelyn’s Story #SCRI #PatientStories #HopeInAction

011

Sarah Cannon Research Institute @scri.com · 07/06/2026

Today, we celebrate survivors—and the strength behind every story. 💙 National Cancer Survivor’s Day is a reminder of what’s possible with courage, compassionate care, and progress in research. Today- and every day - we celebrate you. #NationalCancerSurvivorsDay #CancerSurvivor #HopeInAction #SCRI

000

Sarah Cannon Research Institute @scri.com · 05/06/2026

Meet Jim, who chose a clinical trial as his first step in treatment—close to home through SCRI and SCRI Oncology Partners. His story highlights how trials can be an active, empowering choice in care. 🔗 Read more at the link in bio #EveryClinicalTrialTellsAStory #SCRI

010

Sarah Cannon Research Institute @scri.com · 01/06/2026

Wrapping up strong at #ASCO26 with SCRI Meet the Expert sessions in GI, breast, and innovation in trial delivery through Accelero. Come connect with our teams!

000

Sarah Cannon Research Institute @scri.com · 31/05/2026

Meet SCRI experts at #ASCO26 for a lymphoma session led by Krish Patel MD. Join the conversation and learn how we are advancing research for patients.

000

Sarah Cannon Research Institute @scri.com · 31/05/2026

Tomorrow is Day 4 at #ASCO26. Catch SCRI experts leading key sessions and sharing insights on advancing cancer care in community settings. From trial innovation to real-world impact, we’re proud to help shape what’s next in oncology.

000

Sarah Cannon Research Institute @scri.com · 30/05/2026

Tomorrow is Day 3 at #ASCO26. Catch SCRI experts presenting the latest research in hematologic cancers and solid tumors, including Dr. Melissa Johnson, Dr. Peter Forsberg, Dr. Debra Patt, Dr. Elisa Fontana and Dr. James Essell.

000

Sarah Cannon Research Institute @scri.com · 30/05/2026

Join SCRI at #ASCO26 for Meet the Expert sessions on head and neck cancer, myeloma, leukemia and melanoma. Connect with our investigators at booth 22035.

000

Sarah Cannon Research Institute @scri.com · 29/05/2026

At #ASCO26, join us for Conquering Veteran Cancer, Together — Sun, May 31 | 9:30–11:30 a.m. CT at Hyatt Regency. Proud our CEO Dee Anna Smith is speaking. Register: bmsmeetings.cventevents.com/gqmKoN

020

Sarah Cannon Research Institute @scri.com · 29/05/2026

Day 1 of #ASCO26 is here. Our experts are presenting the latest research in hematologic disorders & more. Dr. Hans Lee will share first results from the Phase 1/2 LINKER-AL2 trial. #SCRI #OncologyLeadership #CancerResearch

000

Sarah Cannon Research Institute @scri.com · 28/05/2026

SCRI is advancing cancer research through community-based clinical trials and decades of innovation. Explore our latest insights from #ASCO26: www.scri.com/asco

000

Sarah Cannon Research Institute @scri.com · 22/05/2026

Some stories are measured in decades. 💙 20 years ago, Lisa joined a clinical trial through @texasoncology.bsky.social & SCRI—just after having her first child. Today, Lisa is thriving & that child is in college. 🔗 Read her story: link in bio #EveryClinicalTrialTellsAStory

000

Sarah Cannon Research Institute @scri.com · 20/05/2026

Clinical trials are key to advancing cancer care—and understanding them can open new possibilities. This #ClinicalTrialsDay, we’re sharing 5 things to know about trials and how they may support your care journey. 🔗 Learn more: scri.com/patients/faqs #SCRI

000

Sarah Cannon Research Institute @scri.com · 20/05/2026

SCRI announces a strategic oncology collaboration w/ Pfizer to accelerate clinical trials and expand patient access to promising therapies—marking #ClinicalTrialsDay and advancing research w/ our Accelero™ model, delivering trials faster, closer to home. www.scri.com/news/sarah-c...

000

Sarah Cannon Research Institute @scri.com · 15/05/2026

Two relapses. A new path forward. After Waldenström macroglobulinemia returned twice, Carol joined an SCRI clinical trial at Colorado Blood Cancer Institute. More than a year later, she’s doing well—and back to what she loves. Read her story: scri.com/patients/carol

000

Sarah Cannon Research Institute @scri.com · 11/05/2026

Meet JP, a patient who participated in a clinical trial close to home at Oncology Hematology Care (OHC) through SCRI. His story highlights the importance of trust, access, & community based research—where patients are supported every step of the way. 🔗 www.scri.com/patients/jp/

000

Sarah Cannon Research Institute @scri.com · 30/03/2026

On #DoctorsDay, we celebrate the physicians across #SCRI who are driving innovation, advancing clinical research, and putting patients first every day. Your leadership, curiosity, and commitment are shaping the future of cancer care. Thank you for all you do. #PhysicianLeadership #ClinicalTrials

000

Sarah Cannon Research Institute @scri.com · 11/12/2025

Congrats to our SCRI team for powering 100 abstracts & 50+ investigator-led presentations across hematologic diseases. Patients remain at the center of all we do—here’s to driving impact beyond Orlando! #SCRI

000

Sarah Cannon Research Institute @scri.com · 08/12/2025

Didn’t have a chance to meet our experts at #ASH25 booth 1580? Learn from them during their presentations today! View the schedule: scriash2025.com

000

Sarah Cannon Research Institute @scri.com · 07/12/2025

Meet #SCRI experts at #ASH25. Visit booth 1580 and view our full schedule: uberflip.scri.com/i/1541695-me...?

000

Sarah Cannon Research Institute @scri.com · 07/12/2025

Dr. Burke takes the #ASH25 stage to answer the question: How Can Community-Based and Academic Hematologists Foster Clinical Trial Participation as Part of Patient Care?

000

Sarah Cannon Research Institute @scri.com · 06/12/2025

Dr. Frangoul presents first results of exagamglogene autotemcel in children aged 5–11 with transfusion‑dependent β‑thalassemia or #SCD with recurrent severe VOCs. A major moment for pediatric gene‑edited therapy research. #ASH25

010

Sarah Cannon Research Institute @scri.com · 06/12/2025

🔬 Featured at #ASH25 Dr. Burke presented new Phase II MorningSun data on fixed‑duration subcutaneous mosunetuzumab with maintenance therapy for previously untreated high‑tumor‑burden follicular #lymphoma (HTB FL).

000

Sarah Cannon Research Institute @scri.com · 06/12/2025

SCRI expert, Dr. Hans Lee serves as session chair during “#MultipleMyeloma: Pharmacologic Therapies: Advances in Treatment Strategies for Relapsed/Refractory Multiple Myeloma.” #ASH25

010

Sarah Cannon Research Institute @scri.com · 06/12/2025

From AGAVE‑201, Dr. Farhadfar reports that switching to axatilimab 0.6 mg/kg Q4W was safe, feasible, and showed no new signals vs 0.3 mg/kg Q2W. Patients remained on therapy long‑term (median 1.7 y), with 84% continuing—suggesting ongoing benefit. #ASH25

000

Sarah Cannon Research Institute @scri.com · 04/12/2025

Hematology is evolving fast, and SCRI experts are leading the way. Ahead of #ASH25, explore 5 trends shaping research and collaboration this year. Read more: www.scri.com/news/sarah-c... #SCRI #ASH25 #Hematology #Oncology

010

Sarah Cannon Research Institute @scri.com · 02/12/2025

Sarah Cannon Research Institute will present 100 abstracts at #ASH25, marking our largest presence yet. 50+ investigators will share breakthroughs in blood cancers & disorders. Learn more: www.scri.com/news/sarah-c...

000

Sarah Cannon Research Institute @scri.com · 12/11/2025

We’re expanding our collaboration with @bmsnews to accelerate cancer research and broaden access to clinical trials through SCRI’s Accelero model. Read more: www.scri.com/news/sarah-c... #CancerResearch #ClinicalTrials

000

Sarah Cannon Research Institute @scri.com · 07/11/2025

November is #LungCancerAwarenessMonth. #SCRI's Dr. Melissa Johnson joined NewsChannel 5 to discuss how early detection and clinical trials are transforming lung cancer care. From low-dose CT scans to bispecifics, the future of treatment is here. www.newschannel5.com/news/let-me-...

010

Sarah Cannon Research Institute @scri.com · 09/10/2025

Your breast cancer risk is personal—and understanding it is powerful. SCRI's Dr. Denise Yardley shares how genetic testing is changing prevention on @newschannel5plus.bsky.social . 🎥 Watch: bit.ly/DrYardleyBCAM #BCAM #BreastCancerAwareness #EarlyDetection #SCRI

000

Sarah Cannon Research Institute @scri.com · 06/10/2025

We’re celebrating Dr. Howard “Skip” Burris’s remarkable career as he prepares to retire as President & CMO of SCRI. His legacy: 850+ first-in-human trials, countless lives impacted. 💙 Welcome new leaders and read the full update: www.scri.com/news/scri-an...

010

Sarah Cannon Research Institute @scri.com · 02/10/2025

At 45, Bryan was diagnosed with advanced prostate cancer. A BRCA mutation led him to a clinical trial through SCRI at Texas Oncology. Today, his PSA levels are undetectable—and he’s thriving. 💙 #ProstateCancer #BRCA #SCRI #TexasOncology #USOncologyNetwork #ClinicalTrials #CancerResearch

000

Sarah Cannon Research Institute @scri.com · 29/09/2025

Bill, 76, joined a clinical trial at SCRI to treat stage IV prostate cancer. His goal: dance at his daughter’s wedding. ✅ Now celebrating a grandchild & still practicing law—while seeing a 15% reduction in disease. Hope lives here. 🔗 www.scri.com/patients/?co... #SCRI #ClinicalTrials #ProstateCancer

000

Sarah Cannon Research Institute @scri.com · 25/09/2025

Mary is proof that hope and research go hand in hand. She’s in a clinical trial for IV #ovariancancer at #SCRI at Mary Crowley—and her disease has remained stable since March. She’s walked the Camino de Santiago, joined the Lourdes Pilgrimage, & got a tattoo to celebrate it all. #PatientStories

010

Sarah Cannon Research Institute @scri.com · 02/09/2025

Joseph, a physician & mountain biking coach, was diagnosed with AML in 2023. A clinical trial at SCRI helped him return to biking, coaching, and living fully. 💬 Read his story: www.scri.com/patients/?co... #AML #SCRI #ClinicalTrials #Hope

000

Sarah Cannon Research Institute @scri.com · 25/08/2025

Kim’s story is a powerful reminder of what clinical trials can offer. After receiving treatment through SCRI and Alliance Cancer Specialists, today, she’s an advocate, fundraiser, and survivor. www.scri.com/patients/?co... #SCRI #OvarianCancerAwareness #ClinicalTrialsMatter #PatientStories

010

Sarah Cannon Research Institute @scri.com · 19/08/2025

Lisa’s story is one of resilience and research. Diagnosed with triple-negative breast cancer while pregnant, she beat the odds through a clinical trial at SCRI. Nearly 20 years later, she’s cancer-free — and her journey continues to inspire. www.scri.com/patients/?co... #PatientStories

000

Sarah Cannon Research Institute @scri.com · 13/08/2025

JP was diagnosed with stage IV lung cancer. He joined a clinical trial through SCRII at OHC—and responded to immunotherapy. Now in remission, he celebrates each year with a cake and a message of hope. 🎂 #SCRI #CancerSurvivor #Immunotherapy #ClinicalResearch www.scri.com/patients/?co...

000

Sarah Cannon Research Institute @scri.com · 30/07/2025

💡 Why consider a clinical trial during your cancer journey? ✨ Access cutting-edge treatments ✨ Stay close to home ✨ Help shape the future of cancer care 🎥 Watch our latest video to learn more: www.scri.com/patients/ #CancerAwareness #ClinicalTrials #OncologyResearch #SCRI #HopeCloseToHome

000

Sarah Cannon Research Institute @scri.com · 05/06/2025

Thank you, #ASCO25! We’re grateful to our presenters, panelists, and the entire ASCO community for an inspiring week of innovation and collaboration. Here’s to advancing therapies for patients —together. Until next year! #SCRI #CancerResearch #OncologyLeadership #ThankYouASCO

011

Sarah Cannon Research Institute @scri.com · 03/06/2025

Dr. Meredith McKean delivers her oral presentation on Novel Targets in #Melanoma Treatment at #ASCO2025

021

Sarah Cannon Research Institute @scri.com · 02/06/2025

Dr. Naqash serves as chair in the Oral Abstract Session: Lung Cancer-Non-Small Cell Local-Regional/ Small Cell/ Other Thoracic Cancers session. #ASCO25

010

Sarah Cannon Research Institute @scri.com · 02/06/2025

🚨 LIVE from #ASCO25 🚨 Dr. Erika Hamilton presents first-in-human data on Emi-Le (B7-H4 ADC) in solid tumors. 🔹 ORR: 31% in B7-H4 high 🔹 ORR: 44% w/ ≤4 prior lines 🔹 ACC-I: 55.6% ORR Promising activity + tolerability in mBC, OC, EC & ACC-I. #SCRI #ADC #Oncology #ASCO2025

021

Sarah Cannon Research Institute @scri.com · 02/06/2025

We look forward to seeing more of you on day four of the #ASCO25 Annual Meeting. Stop by both #27022 to meet experts from across the network, from 9:45am-2:00pm. #CancerResearch uberflip.scri.com/i/1535506-me...

000

Sarah Cannon Research Institute @scri.com · 01/06/2025

Dr. Johnson tackled how community oncology can deliver cutting-edge lung cancer therapies: 🔹 Not all bispecifics need inpatient care 🔹 Tarlatamab = outpatient-friendly 🔹 Innovative care models = better access #LungCancer #Immunotherapy #SCRI #ASCO25

000

Sarah Cannon Research Institute @scri.com · 01/06/2025

🔬 At #ASCO25, Dr. Naqash explored the promise & challenges of bispecific T-cell engagers (BiTEs) in lung cancer & beyond: ✅ Tarlatamab earns FDA nod for SCLC ⚠️ CRS & ICANS toxicity management is key 🎯 DLL3 & other targets may expand BiTE reach #Immunotherapy #LungCancer #SCRI

010

Sarah Cannon Research Institute @scri.com · 31/05/2025

At #ASCO25, Dr. @ErikaHamilton9 presented Phase 3 VERITAC-2 results: 🧬 Vedegestrant (first PROTAC ER degrader) showed: ✅ Significant PFS benefit vs fulvestrant (ESR1m ER+/HER2- ABC) ✅ Favorable safety (<5% AEs led to dose changes) ⏳ OS data maturing A promising new option!

042

Sarah Cannon Research Institute @scri.com · 31/05/2025

Dr. Frangoul and patient, Jimi, take the stage in a powerful #AACR/#ASCO joint session, showcasing both side of what it means to explore real-world gene therapy: successes, challenges & equitable access. #ASCO25

021